サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468506

アルツハイマー病治療薬市場：薬剤クラス別、流通チャネル別、地域別レポート、2024～2032年

Alzheimer's Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.86円
アルツハイマー病治療薬市場：薬剤クラス別、流通チャネル別、地域別レポート、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアルツハイマー病治療薬市場規模は2023年に77億米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて5.3%の成長率（CAGR）を示し、2032年までに124億米ドルに達すると予測しています。アルツハイマー病の有病率の上昇、医薬品開発における数々の進歩、神経変性疾患研究に対する公的・民間資金の増加は、市場を推進する主要要因の一部です。

アルツハイマー病治療薬とは、主に認知機能に影響を及ぼす神経変性疾患であるアルツハイマー病の症状を緩和したり、進行を遅らせたりするために特別に設計された化合物や治療薬を指します。これらの薬剤は、アルツハイマー病に特徴的なアミロイド斑やタウの蓄積など、脳における病態生理学的変化の根底にあるものに対処することを目的としています。コリンエステラーゼ阻害薬とNMDA受容体拮抗薬の2種類に大別されます。ドネペジル、リバスチグミン、ガランタミンのようなコリンエステラーゼ阻害薬は、脳内の神経伝達物質のレベルを上昇させ、認知機能を一時的に高めることによって作用します。メマンチンなどのNMDA受容体拮抗薬は、グルタミン酸の活性を調節し、認知症状や行動症状の緩和を助ける。

効果的な治療薬を必要とするアルツハイマー病の有病率の上昇は、予測期間中のアルツハイマー病治療薬市場の成長を刺激すると考えられます。さらに、神経科学における数々の進歩や、潜在的な治療薬の発見につながる疾患の根本的なメカニズムの深い理解により、主要企業による研究開発の取り組みが増加していることも、市場の成長にプラスの影響を与えています。さらに、神経変性疾患研究のための政府や組織による資金配分の増加は、医薬品開発のための環境を促進し、市場成長の触媒となっています。これに加えて、特に新興国市場では高齢化社会が拡大しており、高齢者がアルツハイマー病に罹患しやすくなっていることも市場成長を後押ししています。さらに、新薬や治療薬法に対する規制当局の承認が高まっており、製薬企業が参入してプレゼンスを拡大する機会が生まれていることも、市場の成長に寄与しています。

アルツハイマー病治療薬の市場動向と促進要因：

有病率の上昇

アルツハイマー病の有病率の上昇は、市場の成長を支える重要な要因の1つです。この背景には、世界の急速な高齢化があります。人々が長生きするにつれて、アルツハイマー病を含む加齢に関連する神経変性疾患の発生率が急上昇しています。このような人口動態の変化により、世界の医療システムへの負担は増大の一途をたどっており、効果的な治療薬法が必要とされています。製薬会社は、症状を緩和したり、病気の進行を遅らせる可能性のある医薬品の開発に投資することで、この需要に応えています。さらに、認知度の向上と早期診断は、より多くの症例が確認されるにつれて有病率の上昇に寄与しています。その結果、有病率が市場を牽引し、アルツハイマー病がもたらす医療課題に対処するための研究とイノベーションの緊急の必要性を強調しています。

調査における急速な進歩

分子と細胞レベルでのアルツハイマー病に対する理解の進歩は、市場の極めて重要な促進要因です。研究者は、脳の変性におけるアミロイド斑やタウタンパク質のもつれの役割など、この疾患の背後にある複雑なメカニズムを解明しつつあります。これらの知見は、医薬品開発の貴重な対象となります。さらに、遺伝学的研究により、アルツハイマー病に対する感受性を高める遺伝的要因が明らかになりつつあり、創薬への取り組みがさらに導かれています。ゲノム解析、神経画像解析、バイオマーカー解析などの最先端技術は、臨床試験や薬効評価を容易にしています。このような研究開発は、アルツハイマー病治療薬のレパートリーを増やし、その有効性を向上させ、患者の予後を改善する希望をもたらします。

政府の資金援助と支援の増加

世界中の政府や医療機関は、アルツハイマー病を公衆衛生の危機として認識しつつあります。介護者の負担や医療費など、この疾患の経済的・社会的影響が大きいことから、アルツハイマー病の研究や医薬品開発に対する資金援助が増加しています。政府からの助成金、研究提携、製薬会社に対する奨励金などがより一般的になってきています。このような財政的支援は、現在進行中の研究努力を後押しし、製薬業界によるアルツハイマー病治療薬開発への投資を促しています。さらに、規制当局はアルツハイマー病治療薬の承認プロセスを合理化し、より迅速な市場参入を促進しています。このような官民協働の支援環境において、製薬会社は革新的で効果的なアルツハイマー病治療薬を市場に投入するインセンティブを与えられ、差し迫った世界の医療ニーズに対応しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 アルツハイマー病治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • ドネペジル
  • ガランタミン
  • リバスチグミン
  • メマンチン
  • その他

第7章 市場内訳：流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンラインストア
  • その他

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
図表

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players
目次
Product Code: SR112024A2695

The global Alzheimer's drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.3% during 2024-2032. The rising prevalence of Alzheimer's disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Alzheimer's drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer's disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer's disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

The rising prevalence of Alzheimer's disease that necessitates effective treatments will stimulate the growth of the Alzheimer's drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer's disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer's Drugs Market Trends/Drivers:

Rising prevalence of the disease

The escalating prevalence of Alzheimer's disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer's, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer's disease.

Rapid advancements in research

Advances in the understanding of Alzheimer's disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer's, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer's drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer's disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer's research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer's drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer's drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer's treatments to the market, addressing a pressing global healthcare need.

Alzheimer's Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global Alzheimer's drugs market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Donepezil

Galantamine

Rivastigmine

Memantine

Others

Donepezil represents the most popular drug class

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer's disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer's, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer's to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer's continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer's drugs market.

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Stores

Others

Hospital pharmacy accounts for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer's medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer's drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer's drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer's primarily affects older individuals. This demographic trend increases the demand for Alzheimer's drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer's drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer's disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer's drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape:

Key players in the Alzheimer's drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer's treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer's. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer's. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

AstraZeneca PLC

Biogen Inc.

Daiichi Sankyo Company Limited

Eisai Co. Ltd.

Eli Lilly and Company

H. Lundbeck A/S

F. Hoffmann-La Roche AG

Merck & Co. Inc.

Novartis AG

Ono Pharmaceutical Co. Ltd.

Pfizer Inc

Teva Pharmaceutical Industries Limited

Recent Developments:

In July 2023, AbbVie Inc., a leading global biopharmaceutical company, announced the expansion of its strategic collaboration with Calibr, a nonprofit drug discovery division of Scripps Research. This collaboration aims to propel the development of multiple preclinical and early-stage clinical assets in the field of biopharmaceuticals. Building upon their existing partnership, this expansion signifies a commitment to advancing innovative therapies for various diseases.

In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer's disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer's disease, creates a powerful synergy.

In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (AB) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease. This development marks a significant milestone in the pursuit of effective Alzheimer's treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer's disease by targeting AB protofibrils, which are thought to contribute to disease progression.

Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis